胰高血糖素样肽-1受体激动剂的研究进展

553 中南药学 2017 年 5 月 第 15 卷 第 5 期　Central South Pharmacy. May 2017, Vol. 15 No.5 ma-（4-Aryl-1-piperazinyl）-l-prolyl] thiazolidines as a novel series of highly potent and long-lasting DPP-Ⅳ in-hibitors [J]. Bioorg Med Chem Lett，2007，17（9）：2618- 2621. [32] Forst T，Uhliglaske B，Ring A，et al. Linagliptin（BI 1356）， a potent and selective DPP-4 inhibitor，is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes [J]. Diabetic Med，2010，27（12）： 1409-1419. [33] Chyan YJ，Chuang LM. Dipeptidyl peptidase-Ⅳ inhib-itors：An evolving treatment for type 2 diabetes from the incretin concept [J]. Recent Pat Endocr Metab Immune Drug Discov，2007，1（1）： 15-24. [34] Pei Z，Li X，von Geldern TW，et al. Discovery and structure-activity relationships of piperidinone and piperidine-constrained phenethylamines as novel，po-tent，and selective dipeptidyl peptidase Ⅳ inhibitors [J]. J Med Chem，2007，50（8）： 1983-1987. [35] Cox JM，Edmondson SD，Harper B，et al. Aminopiperi-dines as dipeptidyl peptidase-Ⅳ inhibitors for the treatment or prevention of diabetes：U. S. Patent 7，884，104[P]. 2011-02-08. [36] Kim HJ，Kwak WY，Min JP，et al. Discovery of DA- 1229：a potent，long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes [J]. Bioorg Med Chem Lett，2011，21（12）： 3809-3812. [37] Biftu T，Sinha-Roy R，Chen P，et al. Omarigliptin（MK-3102）：a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. [J]. J Med Chem，2014，57 （8）： 3205-32